Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model

Nature Neuroscience

Volumn 8, Issue 10, 2005, Pages 1343-1349

  Singer, Oded ^a   Marr, Robert A ^a   Rockenstein, Edward ^b   Crews, Leslie ^b   Coufal, Nicole G ^a   Gage, Fred H ^a   Verma, Inder M ^a   Masliah, Eliezer ^b,c  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; LENTIVIRUS VECTOR; RECOMBINANT ENZYME; SMALL INTERFERING RNA;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; DEGENERATIVE DISEASE; EMBRYO; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; MOUSE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; TRANSGENIC MOUSE; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANALYSIS OF VARIANCE; ANIMALS; ASPARTIC ENDOPEPTIDASES; BRAIN; CELL LINE; CLONING, MOLECULAR; DISEASE MODELS, ANIMAL; ENDOPEPTIDASES; GENE EXPRESSION REGULATION; GENETIC VECTORS; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; IMMUNOHISTOCHEMISTRY; LENTIVIRUS; MAZE LEARNING; MICE; MICE, TRANSGENIC; MICROTUBULE-ASSOCIATED PROTEINS; MOLECULAR SEQUENCE DATA; RNA, SMALL INTERFERING; SPATIAL BEHAVIOR; TIME FACTORS;

EID: 27744588007     PISSN: 10976256     EISSN: None     Source Type: Journal    
DOI: 10.1038/nn1531     Document Type: Article

References (49)

1. Sinha, S. et al. Recent advances in the understanding of the processing of APP to beta amyloid peptide. Ann. NY Acad. Sci. 920, 206-208 (2000).
2. Kamenetz, F. et al. APP processing and synaptic function. Neuron 37, 925-937 (2003).
3. Selkoe, D.J. & Schenk, D. Alzheimer's disease: Molecular understanding predicts amyloid-based therapeutics. Annu. Rev. Pharmacol. Toxicol. 43, 545-584 (2003).
4. Citron, M. Emerging Alzheimer's disease therapies: inhibition of β-secretase. Neurobiol. Aging 23, 1017-1022 (2002).
5. Sinha, S. et al. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 402, 537-540 (1999).
6. Esler, W.P. & Wolfe, M.S. A portrait of Alzheimer secretases-new features and familiar faces. Science 293, 1449-1454 (2001).
7. Selkoe, D. et al. Beta-amyloid precursor protein of Alzheimer disease occurs as 110-to 135-kilodalton membrane-associated proteins in neural and nonneural tissue. Proc. Natl. Acad. Sci. USA 85, 7341-7345 (1988).
8. Selkoe, D.J. et al. The role of APP processing and trafficking pathways in the formation of amyloid beta-protein. Ann. NY Acad. Sci. 777, 57-64 (1996).
9. Dingwall, C. Spotlight on BACE: the secretases as targets for treatment in Alzheimer disease. J. Clin. Invest. 108, 1243-1246 (2001).
10. Shen, J. et al. Skeletal and CNS deficits in Presenilin-1-deficient mice. Cell 89, 629-639 (1997).
11. Roberds, S.L. et al. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum. Mol. Genet. 10, 1317-1324 (2001).
12. Ohno, M. et al. BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of alzheimer's disease. Neuron 41, 27-33 (2004).
13. Li, R. et al. Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Proc. Natl. Acad. Sci. USA 101, 3632-3637 (2004).
14. Holsinger, R.M., McLean, C.A., Beyreuther, K., Masters, C.L. & Evin, G. Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. Ann. Neurol. 51, 783-786 (2002).
15. Fukumoto, H., Cheung, B.S., Hyman, B.T. & Irizarry, M.C. Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch. Neurol. 59, 1381-1389 (2002).
16. Vassar, R. The beta-secretase, BACE: a prime drug target for Alzheimer's disease. J. Mol. Neurosci. 17, 157-170 (2001).
17. Hong, L. et al. Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. Science 290, 150-153 (2000).
18. Miller, V.M., Gouvion, C.M., Davidson, B.L. & Paulson, H.L. Targeting Alzheimer's disease genes with RNA interference: an efficient strategy for silencing mutant alleles. Nucleic Acids Res. 32, 661-668 (2004).
19. Tiscornia, G., Singer, O., Ikawa, M. & Verma, I.M. A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proc. Natl. Acad. Sci. USA 100, 1844-1848 (2003).
20. Naldini, L. et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272, 263-267 (1996).
21. Tuszynski, M.H. Gene therapy for neurological disease. Expert Opin. Biol. Ther. 3, 815-828 (2003).
22. Marr, R.A. et al. Neprilysin gene transfer reduces human amyloid pathology intransgenic mice. J. Neurosci. 23, 1992-1996 (2003).
23. Davidson, B.L. & Paulson, H.L. Molecular medicine for the brain: silencing of disease genes with RNA interference. Lancet Neurol. 3, 145-149 (2004).
24. Kao, S.C., Krichevsky, A.M., Kosik, K.S. & Tsai, L.H. BACE1 suppression by RNA interference in primary cortical neurons. J. Biol. Chem. 279, 1942-1949 (2004).
25. Takahashi, R.H. et al. Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain. J. Neurosci. 24, 3592-3599 (2004).
26. Kayed, R. et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-489 (2003).
27. Lacor, P.N. et al. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J. Neurosci. 24, 10191-10200 (2004).
28. Walsh, D.M. et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539 (2002).
29. Kim, H.S. et al. Carboxyl-terminal fragment of Alzheimer's APP destabilizes calcium homeostasis and renders neuronal cells vulnerable to excitotoxicity. FASEB J. 14, 1508-1517 (2000).
30. Song, D.K. et al. Behavioral and neuropathologic changes induced by central injection of carboxyl-terminal fragment of beta-amyloid precursor protein in mice. J. Neurochem. 71, 875-878 (1998).
31. Oster-Granite, M., McPhie, D., Greenan, J. & Neve, R. Age-dependent neuronal and synaptic degradation in mice transgenic for the C terminus of the amyloid procursor protein. J. Neurosci. 16, 6732-6741 (1996).
32. Berger-Sweeney, J. et al. Impairments in learning and memory accompanied by neurodegeneration in mice transgenic for the carboxyl-terminus of the amyloid precursor protein. Brain Res. Mol. Brain Res. 66, 150-162 (1999).
33. 2+ ATPase. Neuroreport 9, 3875-3879 (1998).
34. Xia, H. et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat. Med. 10, 816-820 (2004).
35. Huse, J.T. et al. Beta-secretase processing in the trans-Golgi network preferentially generates truncated amyloid species that accumulate in Alzheimer's disease brain. J. Biol. Chem. 277, 16278-16284 (2002).
36. Rossner, S., Apelt, J., Schliebs, R., Perez-Polo, J.R. & Bigl, V. Neuronal and glial beta-secretase (BACE) protein expression in transgenic Tg2576 mice with amyloid plaque pathology. J. Neurosci. Res. 64, 437-446 (2001).
37. Kitazume, S. et al. Alzheimer's beta-secretase, beta-site amyloid precursor protein-cleaving enzyme, is responsible for cleavage secretion of a Golgi-resident sialyltransferase. Proc. Natl. Acad. Sci. USA 98, 13554-13559 (2001).
38. Kitazume, S. et al. In vivo cleavage of alpha2,6-sialyltransferase by Alzheimer beta-secretase. J. Biol. Chem. 280, 8589-8595 (2005).
39. Wong, H .K. et al. Beta subunits of voltage-gated sodium channels are novel substrates of BACE1 and gamma-secretase. J. Biol. Chem. 280, 23009-23017 (2005).
40. Chang, W.P. et al. In vivo inhibition of Abeta production by memapsin2 (beta-secretase) inhibitors. J. Neurochem. 89, 1409-1416 (2004).
41. Brummelkamp, T.R., Bernards, R. & Agami, R. A system for stable expression of short interfering RNAs in mammalian cells. Science 296, 550-553 (2002).
42. Naldini, L., Blomer, U., Gage, F.H., Trono, D. & Verma, I.M. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc. Natl. Acad. Sci. USA 93, 11382-11388 (1996).
43. Pfeifer, A., Kessler, T., Silletti, S., Cheresh, D.A. & Verma, I.M. Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2. Proc. Natl. Acad. Sci. USA 97, 12227-12232 (2000).
44. Mucke, L. et al. High-level neuronal expression of Aβ 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20, 4050-4058 (2000).
45. Masliah, E. et al. Aβ1-42 promotes cholinergic sprouting in patients with Alzheimer disease and Lewy body variant of Alzheimer disease. Neurology 61, 206-211 (2003).
46. Masliah, E. et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegenerative disorders. Science 287, 1265-1269 (2000).
47. Rockenstein, E. et al. High beta-secretase activity elicits neurodegeneration in transgenic mice despite reductions in amyloid-beta levels: implications for the treatment of Alzheimer's disease. J. Biol. Chem., published online 15 July 2005 (doi:10.1074/jbc.M507016200).
48. Rockenstein, E., Mallory, M., Mante, M., Sisk, A. & Masliah, E. Early formation of mature amyloid-b proteins deposits in a mutant APP transgenic model depends on levels of Ab1-42. J. Neurosci. Res. 66, 573-582 (2001).
49. Rockenstein, E. et al. The neuroprotective effects of Cerebrolysin in a transgenic model of Alzheimer's disease are associated with improved behavioral performance. J. Neural Transm. 110, 1313-1327 (2003).